Cullinan Therapeutics Future Growth
Future criteria checks 2/6
Cullinan Therapeutics's earnings are forecast to decline at 7.1% per annum while its annual revenue is expected to grow at 54.5% per year. EPS is expected to grow by 4% per annum. Return on equity is forecast to be -30.5% in 3 years.
Key information
-7.1%
Earnings growth rate
4.0%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 54.5% |
Future return on equity | -30.5% |
Analyst coverage | Good |
Last updated | 01 May 2024 |
Recent future growth updates
Recent updates
Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth
Apr 23Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Sep 14Cullinan Oncology grants stock options for 125.7K shares
Sep 02Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Jun 24Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 05Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Oct 08Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
Jun 30Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 05Cullinan initiated Buy at H.C. Wainwright on pipeline strength
Feb 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 26 | -203 | N/A | -187 | 7 |
12/31/2025 | 13 | -189 | N/A | -157 | 8 |
12/31/2024 | 2 | -175 | N/A | -131 | 7 |
12/31/2023 | N/A | -153 | -134 | -134 | N/A |
9/30/2023 | N/A | -156 | -142 | -141 | N/A |
6/30/2023 | N/A | -142 | -163 | -161 | N/A |
3/31/2023 | N/A | 65 | -157 | -156 | N/A |
12/31/2022 | N/A | 111 | -128 | -127 | N/A |
9/30/2022 | N/A | 105 | -117 | -117 | N/A |
6/30/2022 | N/A | 113 | -73 | -73 | N/A |
3/31/2022 | N/A | -78 | -64 | -64 | N/A |
12/31/2021 | 19 | -66 | -43 | -43 | N/A |
9/30/2021 | 19 | -61 | -38 | -38 | N/A |
6/30/2021 | 19 | -54 | -36 | -36 | N/A |
3/31/2021 | 19 | -47 | -26 | -26 | N/A |
12/31/2020 | N/A | -52 | -30 | -30 | N/A |
9/30/2020 | N/A | -28 | -25 | -25 | N/A |
6/30/2020 | N/A | -25 | -22 | -22 | N/A |
3/31/2020 | N/A | -21 | -21 | -21 | N/A |
12/31/2019 | N/A | -21 | -21 | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CGEM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CGEM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CGEM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CGEM's revenue (54.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: CGEM's revenue (54.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CGEM is forecast to be unprofitable in 3 years.